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Recombinant human erythropoietin (r-HuEpo) has been used
for the treatment of renal anemia. With the loss of its patent
protection, there has been an upsurge of more affordable
biosimilar agents, increasing patient access to treatment for
these conditions. The complexity of the manufacturing
process for these recombinant proteins, however, can result
in altered properties that may significantly affect patient
safety. As it is not known whether various r-HuEpo products
can be safely interchanged, we studied 30 patients with
chronic kidney disease treated by subcutaneous injection
with biosimilar r-HuEpo and who developed a sudden loss of
efficacy. Sera from 23 of these patients were positive for r-
HuEpo-neutralizing antibodies, and their bone marrow
biopsies indicated pure red-cell aplasia, indicating the loss of
erythroblasts. Sera and bone marrow biopsies from the
remaining seven patients were negative for anti-r-HuEpo
antibodies and red-cell aplasia, respectively. The cause for r-
HuEpo hyporesponsiveness was occult gastrointestinal
bleeding. Thus, subcutaneous injection of biosimilar r-HuEpo
can cause adverse immunological effects. A large, long-term,
pharmacovigilance study is necessary to monitor and ensure
patient safety for these agents.
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Recombinant human erythropoietin (r-HuEpo) was the first
biotherapeutic medicinal product derived from recombinant
DNA technology for the treatment of anemia in patients with
chronic kidney disease (CKD). Although r-HuEpo raises
hemoglobin (Hb) levels in CKD and improves morbidity
associated with anemia in CKD patients, the adverse
immunological effect of innovative r-HuEpo administered
subcutaneously can result in anti-r-HuEpo-associated pure
red-cell aplasia (PRCA) in some patients.1–5 With the
expiration of patent protection for the innovative r-HuEpo,
many so-called ‘similar’ biological r-HuEpos became avail-
able and were licensed as ‘biosimilar r-HuEpos’.6 These
biosimilar r-HuEpos are more affordable, allowing patients
with CKD easy access to treatment for renal anemia
worldwide. Aside from the complexities of the biopharma-
ceutical manufacturing process, variations in host cells,
vector, DNA sequence, or the purification and glycosylation
processes can result in alterations from the reference
innovative r-HuEpo product. Such alterations may cause
impurities or aggregation of the protein that may augment
the immune response and can have major biological impact.7
Because there are few preclinical and clinical comparisons
between each biosimilar r-HuEpo and its reference product,
therefore it is unknown whether r-HuEpo products can be
interchangeable or substituted. This continues to be a
dilemma for many clinicians in treating anemia in CKD
patients.
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EDITOR’S NOTE:
Biosimilar is a term applied to subsequent versions of biopharmaceutical
products that have been approved by the regulatory authorities of a
given country. The pathway for approval is thus specific for that country,
and because of regulatory differences, the biosimilar classification may
not apply in other countries.
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As for Thailand, the first innovative r-HuEpo-a form was
licensed in 1990 and the innovative r-HuEpo-b was approved
for use in 1998. The first biosimilar r-HuEpo-a form became
available in 1997 for the treatment of anemia of CKD. Since
then, there has been an explosion of biosimilar r-HuEpo
products in the Thai drug market. Under the generic drug
paradigm of the Thai Food and Drug Administration, 14
biosimilar r-HuEpos were licensed by 1 January 2009. These
products came from various countries such as Argentina,
China, South Korea, and India. The number of cases using
biosimilar r-HuEpos have increased enormously because of
their more affordable prices. With their usage, adverse effects
of the less than identical therapeutic agents have started to
increase. Many clinicians in Thailand were starting to see an
increase in PRCA cases which raised an important issue
whether the immunogenicity of biosimilar therapeutic agents
were indeed equivalent to the innovative r-HuEpo.
As we are the only center to assay anti-r-HuEpo in
Thailand, we decided to conduct a pilot study to investigate
whether there were presences of anti-r-HuEpo antibody in
CKD patients who received subcutaneous biosimilar
r-HuEpo injections for the treatment of renal anemia and
developed loss of efficacy (LOE).
RESULTS
Patients
A total of 30 CKD patients who received subcutaneous
injections of biosimilar r-HuEpo had LOE during 2008. All
patients had not been treated with any innovative r-HuEpo
agents before using biosimilar r-HuEpo products. Table 1
shows the patients’ characteristics, issues related to the use of
biosimilar r-HuEpo, and laboratory results. There were no
statistically significant differences in gender, age, CKD status,
dialysis modality, CKD etiology, intact parathyroid hormone
levels, r-HuEpo doses, and Hb levels before LOE between
anti-r-HuEpo-positive and -negative patients. However, there
were statistically significant differences in duration of r-
HuEpo exposure, Hb levels at time of LOE, and counts of
reticulocytes between the anti-r-HuEpo-positive and -nega-
tive patients (Table 1). The iron studies, serum folate, and B12
level were adequate and comparable in both groups. The
mean duration of biosimilar r-HuEpo exposure in antibody-
positive patients were significantly shorter than antibody-
negative patients (P¼ 0.001). The antibody-positive patients
had more severe anemia and lower counts of reticulocytes
when compared with the antibody-negative patients. The
mean age of negative control was 54.1±13.9 years. All
negative control cases had Hb levels between 10 and 12 g/dl
with mean r-HuEpo doses of 120±37 unit/kg/week. The
mean age of pure negative control was 32.3±5.9 years. All
pure negative control cases had Hb levels more than 12 g/dl.
Anti-r-HuEpo antibody
The mean duration of developing LOE and anti-r-HuEpo
testing were 1.5±0.5 months. By radioimmunoprecipitation
assay, anti-r-HuEpo was detected in 23 patients. Samples with
a total counts per minute (c.p.m.) of more than 0.9% at 1:20
dilution was considered positive for anti-r-HuEpo. From the
Table 1 | Patients’ characteristics and issues related to the use of biosimilar r-HuEpo and laboratory results
Anti-r-HuEpo positive Anti-r-HuEpo negative P
Numbers of patients (cases) 23 7 —
Gender, male/female (case/case) 13/10 3/4 0.526
Age, years±s.d. 61.1±21.4 52.8±4.8 0.784
CKD status, cases (%) 0.647
Predialysis 8 (34.8) 2 (28.6)
Hemodialysis 14 (60.9) 4 (57.1)
Peritoneal dialysis 1 (4.3) 1 (14.3)
Etiology of CKD, cases (%) 0.393
Diabetic nephropathy 5 (26.1) 3 (42.9)
Chronic glomerulonephritis 3 (13.0) 0
Unknown 14 (60.9) 4 (57.1)
r-HuEpo exposure duration, months±s.d. (range in months) 12.1±7.8 (3–36) 22.3±19.8 (6–60) 0.001*
r-HuEpo dose, U/kg/week±s.d. 149±82 171±91 0.991
Hb before LOE, g/dl±s.d. 10.8±1.6 11.4±0.7 0.458
Hemoglobin by the time of LOE, g/dl±s.d. 5.6±0.9 7.3±0.7 o0.001*
Reticulocytes, cell/mm3±s.d. 5978±1217 13,128±3,456 o0.001*
Serum ferritin, ng/ml±s.d. 368.6±83.1 370.3±93.7 0.967
Transferring saturation, %±s.d. 28.3±6.6 28.8±5.2 0.821
Serum folate, pg/ml±s.d. 12.8±4.5 12.5±4.3 0.526
Serum B12, pg/ml±s.d. 258.2±189.2 177.1±84.4 0.123
CRP, mg/l±s.d. 4.22±2.98 3.62±3.56 0.692
iPTH, pg/ml±s.d. 241.4±127.1 284.0±151.6 0.518
Abbreviations: CKD, chronic kidney disease; CRP, C-reactive protein; Hb, hemoglobin; iPTH, intact parathyroid hormone; LOE, loss of efficacy; r-HuEpo, recombinant human
erythropoietin.
*Po0.05.
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titer assay, the mean values of anti-r-HuEpo was 18.2, 12.7,
10.5, 3.5, 1.0, and 0.3% of c.p.m. at 1:20, 1:50, 1:100, 1:1000,
1:10,000, and 1:20,000 dilutions, respectively (Table 2).
Even at 1:10,000 dilution, anti-r-HuEpo was still detected,
indicating that the antibody levels in the positive sera were
extremely high. Through the neutralization assay, all 23
antibody-positive sera were able to inhibit the growth of
UT7/Epo-dependent cell line by more than 25%.
The sera of the remaining seven patients were negative for
anti-r-HuEpo. The mean percentage of total c.p.m. was
o0.9% at 1:20 dilution, which was not different from the
negative and pure negative controls.
Biosimilar r-HuEpo and PRCA
From bone marrow biopsy, all 23 anti-r-HuEpo-positive
cases had PRCA. The bone marrow biopsy revealed
normocellularity with normal myeloid and megakaryocytic
lineages but absence of the erythroid precursor (o5% of
erythroblasts in the bone marrow). Seven patients with
antibody-negative sera did not show PRCA in the bone
marrow biopsy. However, from the endoscopic examination,
we were able to identify the etiology of LOE. The cause of
sudden LOE in these antibody-negative patients was due to
occult gastrointestinal bleeding.
Estimation of risk
Yearly prevalence of dialysis patients in 2008 receiving
r-HuEpo was obtained from the Thai Renal Replacement
Therapy Registry data. In 2008, there were a total of
26,511 chronic dialysis cases receiving r-HuEpo.8 The
prevalence of CKD stage IV (predialysis) was obtained
from a recent epidemiologic survey conducted in Thailand.9
From 63 million people, the prevalence of CKD stage IV was
0.2%. Out of this 0.2%, about 40% had Hb below 10 g/dl
and needed r-HuEpo treatment. From the Thai ESA
registry data, 78% of the patients had received biosimilar
r-HuEpo.
Estimation of risk for anti-r-HuEpo-associated PRCA
was calculated by 23/(26,511þ (63,000,000 0.002 0.4))
 0.78¼ 23/59,990.
Thus, an estimation of the actual cases using biosimilar
r-HuEpo denominator with this complication was 1:2608.
This indicated that 1 out of 2608 patients using biosimilar
r-HuEpo would develop PRCA.
DISCUSSION
The results from our pilot study showed that there was an
immunogenicity risk in using biosimilar r-HuEpo. Even at
1:10,000 dilution of the sera, we were able to detect anti-
r-HuEpo in patients using biosimilar agents. Because of the
nature of the pilot study and its aim to investigate whether
biosimilar agents currently used in Thailand were capable of
producing anti-r-HuEpo, the results could not provide
sufficient information to determine exactly which specific
biosimilar products are directly responsible for causing anti-
r-HuEpo-associated PRCA. However, we can clearly state that
repeated subcutaneous injections of biosimilar agents could
result in the development of anti-r-HuEpo-associated PRCA.
Further studies with a larger sample size and longer follow-
up period are warranted to provide more information in the
use of biosimilar r-HuEpo.
As a matter of fact, the results from this pilot study
prompted the Nephrology Society of Thailand, the Thai
Society of Hematology, the Association of Hospital Pharmacy
(Thailand), and the Adverse Product Reaction Monitoring
Center of the Food and Drug Administration of Thailand to
set up a prospective, immunogenicity surveillance registry of
erythropoiesis-stimulating agent (ESA) with subcutaneous
exposure (http://www.clinicaltrial.gov; registration number
NCT00799019). The primary objective of this registry is to
estimate the incidence of anti-r-HuEpo-associated PRCA
development in patients, and the secondary objective is to
evaluate the efficacy of the currently available ESA products
for the treatment of erythropoietin-deficiency anemia in
Thailand. The study is a multicenter, prospective, cohort
study of patients who are using ESA products according to
normal practice, consistent with its medical indications.
Subjects in the registry are adults receiving or about to
receive, within 1 month, a marketed ESA product adminis-
tered subcutaneously at the time of enrollment. Observations
for the development of immunogenicity effects and PRCA
will be followed in patients for a total of 3 years. The human
leukocyte antigen-A, -B, -DR, and -DQ genotypes of anti-r-
HuEpo-positive cases will be typed to investigate the
association of human leukocyte antigen-associated and
anti-r-HuEpo-associated PRCA. The reason for determining
this relationship was based on results obtained from recent
studies5,10 that showed the genetic susceptibility of human
leukocyte antigen DR B1*09 to anti-r-HuEpo-associated
PRCA in innovative r-HuEpo cases. It will be another 2 more
Table 2 | Total c.p.m. (%) by different sera dilution to detect anti-r-HuEpo-associated PRCA cases in patients using
subcutaneous biosimilar r-HuEpo: antibody-positive and antibody-negative cases, negative control, and pure negative control
Mean of percent c.p.m.±s.d.
1:20 dilution 1:50 dilution 1:100 dilution 1:1000 dilution 1:10,000 dilution 1:20,000 dilution
Anti-r-HuEpo-positive cases (N=23) 18.2±8.8 12.7±9.7 10.5±9.2 3.5±5.0 1.0±1.0 0.3±0.8
Anti-r-HuEpo-negative cases (N=7) 0.2±0.1 NA NA NA NA NA
Negative control (N=30) 0.2±0.1 NA NA NA NA NA
Pure negative control (N=30) 0.2±0.1 NA NA NA NA NA
Abbreviations: c.p.m., counts per minute; NA, not applicable; PRCA, pure red-cell aplasia; r-HuEpo, recombinant human erythropoietin.
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years before we can analyze the data, but we are confident
that the results of this registry study will enlighten us on how
to deal with biosimilar r-HuEpo.
Our data suggested that biosimilar r-HuEpo should not be
licensed through the conventional generic paradigm. A recent
study7 showed that the use of different cell lines used during
the manufacturing processes can alter the biophysical
characteristics of the protein. In Thailand, before 2010,
biosimilar r-HuEpos were licensed using conventional
generic paradigm that mainly focuses on bioequivalence
study. The registration process did not require a clinical study
data and full dossier was not required. Our data demon-
strated that the lack of preclinical and clinical comparisons
between each biosimilar r-HuEpo and its reference product
can create potential gaps in the quality and safety of
biosimilar r-HuEpo, and warrant guidelines on evaluation
of biosimilar r-HuEpo. The generic approach is not suitable
for the licensing biosimilar, as unlike chemical drugs, that
comprise of small molecules and are easily reproducible with
uncanny similarities to the reference products, biotherapeutic
products consist of relatively large and complex structures
that are difficult to characterize. It is essential that both
preclinical and clinical comparisons between biosimilar
agents and their reference products are required11 to ensure
the safety and efficacy of these biosimilar agents. A specific
regulatory framework is now being developed in Thailand.
The key principles for evaluating r-HuEpo biosimilar involve
stepwise comparability exercises, starting with comparison of
the quality characteristics of biosimilar with their reference
biotherapeutic products, which were licensed based on a full
dossier. The comparability exercises include physicochemical
properties, biological activity, immunochemical properties,
impurities, pharmacokinetic/pharmacodynamic studies, effi-
cacy studies, and safety studies. As for most biotherapeutic
products, data from prelicensing are usually too limited to
identify all potential adverse effects; pharmacovigilance plans
and risk management plan should be submitted and
integrated as parts of evaluation.
As for countries that have already licensed biosimilar r-
HuEpo products and are currently in use, such as Thailand,
pharmacovigilance and antibody testing in a large cohort for
a long period of time during the post-marketing phase is
warranted, especially for products administered by subcuta-
neous injections. This is important because there is an
inadequacy of post-marketing surveillance and a lack of
reliable information in regards to the long-term effects of
biosimilar agents. Although there are no reports of anti-r-
HuEpo-associated PRCA from intravenous injection, the
universal implementation of intravenous injection of r-
HuEpo would be impractical for predialysis patients and is
not realistic in countries with limited resources because
higher doses are required to achieve the target Hb.12
In conclusion, we would like to caution against wholesale
adoption of biosimilar r-HuEpo to decrease costs and increase
access to therapy because the patients can develop anti-
r-HuEpo antibodies after subcutaneous injection of biosimilar
r-HuEpo. From this pilot study, the immunogenicity of
biosimilar therapeutic agents is an important issue that
deserves the attention of clinicians and drug regulators. It is
highly recommended that a plan for strict licensing, contin-
uous post-marketing monitoring, and pharmacovigilance
should be implemented to detect, assess, and prevent these
adverse effect in patients using biosimilar r-HuEpo agents.
PATIENTS AND METHODS
Patients
In 2008, 30 CKD patients were referred to our center. CKD patients
who received only subcutaneous injections of biosimilar r-HuEpo
and developed LOE were recruited in this study. Additional 30 CKD
patients who received r-HuEpo but did not develop LOE served as
negative controls. Another 30 CKD patients who have never received
r-HuEpo served as pure negative controls. The study was approved
by the Ethical Committee of Research, Faculty of Medicine,
Chulalongkorn University Hospital, Bangkok, Thailand. Informed
consent was obtained from each patient before entering the study.
Definitions
LOE was defined as a sudden drop in the Hb level more than 2 g/dl
for 2 consecutive weeks resulting in anemic symptoms and the need
for blood transfusions to alleviate anemic symptom every week in
the absence of other common causes of r-HuEpo unresponsiveness,
such as acute blood loss, acute hemolysis, infection, hyperparathy-
roidism, hypothyroidism, and deficiencies of iron, folic acid, and
vitamin B12.
Radioimmunoprecipitation assay for anti-r-HuEpo
Sera from the recruited patients were assayed for anti-r-HuEpo.
Radioimmunoprecipitation assay was used to quantitatively exam-
ine the presence of antibody to r-HuEpo in the sera.13 The serum
samples were incubated with 125iodine-labeled Epo purchased from
PerkinElmer Life Sciences (Boston, MA). The bound antibody was
separated from the free-labeled Epo by using Protein G Sepharose 4
Fast Flow beads (GE Healthcare, Uppsala, Sweden). The beads were
then thoroughly washed and counted on a gamma counter. The
presence of anti-r-HuEpo antibody in the tested sera was
determined by calculating the percent of total c.p.m. The serum
analyzed in the screening assay was reassayed if the percent of total
c.p.m. count was more than 0.3%. The titer assay was performed at
dilutions of 1:20, 1:50, 1:100, 1:1000, 1:10,000, and 1:20,000. Positive
serum for anti-r-HuEPO had a total c.p.m. count more than 0.9% at
1:20 dilution.
Neutralization assay
The sera identified as positive for anti-r-HuEpo were further assayed
for its neutralization activity. Neutralization assay was used to
determine whether the anti-r-HuEpo was capable of inhibiting the
growth of UT-7/Epo-dependent cell line.14 The UT-7/Epo cells were
kindly obtained from Professor Nicole Casadevall (INSERM U 790).
A cell bank was prepared, and the cells were stored in liquid nitrogen
in 10% dimethyl sulfoxide and 90% fetal bovine serum. Thawed UT-
7/Epo cells were grown in a basal medium containing Dulbecco’s
Modified Eagle’s Medium, fetal bovine serum, 50U/ml penicillin G,
50 mg/ml streptomycin sulfate, and L-glutamine. The 3H-thymidine
was obtained from Amersham Bioscience (Piscataway, NJ). The Epo
levels in the sera were measured by the Human Erythropoietin
Quantikine IVD ELISA Kit purchased from R&D Systems
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(Minneapolis, MN). The test sera were diluted depending on the
Epo and anti-r-HuEpo antibody levels, and were later added to the
starved UT-7/Epo cells. r-HuEpo-a was also added at a final
concentration of 10mU/ml. The culture was incubated at 37 1C in
5% CO2 for 48 h. The
3H-thymidine was added, and after 6 h of
incubation, the cells were harvested onto a microfilter to measure
for radioactivity. The test sera were considered to be positive if more
than 25% neutralization was observed.
Statistical analysis
The continuous values of variables were expressed as mean±s.d.
Comparisons of the variables were performed by the independent
sample t-test or w2-test where appropriate. All statistical analyses
were performed by using SPSS statistical package (version 11.5 for
Windows, SPSS, Chicago, IL). A P-value of o0.05 was considered
statistically significant.
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